108 phenotypes from 6 alleles in 8 genetic backgrounds

Allelic Composition Genetic Background	Annotated Term	Reference
Ncoa3tm1.1Bwo/Ncoa3tm1.1Bwo involves: 129S/SvEv * C57BL/6J	abnormal cell differentiation	J:161276
	abnormal defecation	J:161276
	abnormal eating behavior	J:161276
	abnormal exercise endurance	J:161276
	abnormal glucose homeostasis	J:161276
	abnormal hormone level	J:161276
	decreased adiponectin level	J:161276
	decreased body temperature	J:161276
	decreased carbon dioxide production	J:161276
	decreased circulating glucagon level	J:161276
	decreased locomotor activity	J:161276
	decreased oxygen consumption	J:161276
	normal homeostasis/metabolism phenotype	J:161276
	hyperglycemia	J:161276
	impaired adaptive thermogenesis	J:161276
	impaired glucose tolerance	J:161276
	increased body weight	J:161276
	increased circulating insulin-like growth factor I level	J:161276
	increased circulating leptin level	J:161276
	increased fat cell size	J:161276
	increased incidence of tumors by chemical induction	J:161276
	increased liver glycogen level	J:161276
	increased liver triglyceride level	J:161276
	increased total body fat amount	J:161276
	insulin resistance	J:161276
	oliguria	J:161276
Ncoa3tm1b(EUCOMM)Wtsi/Ncoa3+ C57BL/6N-Ncoa3tm1b(EUCOMM)Wtsi/H	abnormal tooth morphology	J:211773
	impaired glucose tolerance	J:211773
	increased circulating bilirubin level	J:211773
	persistence of hyaloid vascular system	J:211773
Ncoa3tm1b(EUCOMM)Wtsi/Ncoa3tm1b(EUCOMM)Wtsi C57BL/6N-Ncoa3tm1b(EUCOMM)Wtsi/H	abnormal tooth morphology	J:211773
	persistence of hyaloid vascular system	J:211773
	preweaning lethality, incomplete penetrance	J:211773
Ncoa3tm1Jxu/Ncoa3tm1Jxu involves: 129S6/SvEvTac	abnormal branching of the mammary ductal tree	J:62724
	abnormal female reproductive system physiology	J:62724
	abnormal mammary gland development	J:62724
	abnormal vagina epithelium morphology	J:62724
	cachexia	J:62724
	decreased body weight	J:62724
	decreased circulating estradiol level	J:62724
	decreased circulating insulin-like growth factor I level	J:62724
	decreased fibroblast cell migration	J:88789
	decreased litter size	J:62724
	decreased superovulation rate	J:62724
	delayed sexual maturation	J:62724
	delayed vaginal opening	J:62724
	disproportionate dwarf	J:62724
	postnatal growth retardation	J:62724
	preweaning lethality, incomplete penetrance	J:62724
	prolonged estrous cycle	J:62724
	rough coat	J:62724
Ncoa3tm1Jxu/Ncoa3tm1Jxu involves: 129S6/SvEvTac * C57BL/6	decreased circulating glucose level	J:120086
	decreased interleukin-1 beta secretion	J:120086
	impaired adaptive thermogenesis	J:120086
	increased circulating interleukin-1 beta level	J:120086
	increased circulating interleukin-6 level	J:120086
	increased circulating tumor necrosis factor level	J:120086
	increased interleukin-6 secretion	J:120086
	increased susceptibility to bacterial infection induced morbidity/mortality	J:120086
	increased susceptibility to endotoxin shock	J:120086
	increased tumor necrosis factor secretion	J:120086
Ncoa3tm1Jxu/Ncoa3tm1Jxu involves: 129S6/SvEvTac * C57BL/6J	abnormal adipose tissue morphology	J:117159
	abnormal B cell morphology	J:109522
	abnormal brown fat cell morphology	J:144060
	abnormal cell differentiation	J:117159
	abnormal epididymal fat pad morphology	J:117159
	abnormal lymphopoiesis	J:109522
	abnormal skeletal muscle fiber morphology	J:144060
	abnormal spleen red pulp morphology	J:109522
	decreased body weight	J:109522, J:117159, J:144060
	decreased brown adipose tissue amount	J:144060
	decreased brown fat cell lipid droplet size	J:144060
	decreased brown fat cell size	J:144060
	decreased circulating cholesterol level	J:144060
	decreased circulating free fatty acids level	J:144060
	decreased circulating glucose level	J:144060
	decreased circulating HDL cholesterol level	J:144060
	decreased circulating insulin level	J:144060
	decreased circulating triglyceride level	J:144060
	decreased epididymal fat pad weight	J:117159
	decreased liver weight	J:144060
	decreased splenocyte apoptosis	J:109522
	decreased susceptibility to diet-induced hepatic steatosis	J:144060
	decreased susceptibility to diet-induced obesity	J:144060
	decreased total body fat amount	J:117159, J:144060
	decreased white adipose tissue amount	J:117159, J:144060
	decreased white fat cell size	J:117159
	enlarged spleen	J:109522
	impaired exercise endurance	J:144060
	improved glucose tolerance	J:144060
	increased B cell derived lymphoma incidence	J:109522
	increased B cell number	J:109522
	increased B cell proliferation	J:109522
	increased carbon dioxide production	J:144060
	increased CD4-positive, alpha-beta T cell number	J:109522
	increased CD8-positive, alpha-beta T cell number	J:109522
	increased energy expenditure	J:144060
	increased insulin sensitivity	J:144060
	increased leukocyte cell number	J:109522
	increased lymphocyte cell number	J:109522
	increased lymphoma incidence	J:109522
	increased mitochondrial size	J:144060
	increased oxygen consumption	J:144060
	increased respiratory quotient	J:144060
	increased spleen germinal center size	J:109522
	increased T cell proliferation	J:109522
	premature death	J:109522
	small liver	J:144060
	thrombocytopenia	J:109522
Ncoa3tm1Rsd/Ncoa3tm1Rsd involves: 129S1/Sv * 129X1/SvJ * C57BL/6	abnormal cell physiology	J:66454
	decreased body size	J:66454
	decreased body weight	J:66454
	decreased cell proliferation	J:66454
	decreased circulating insulin-like growth factor I level	J:66454
	decreased embryo size	J:66454
	normal endocrine/exocrine gland phenotype	J:66454
	lowered ear position	J:66454
Ncoa3tm2.1Jxu/Ncoa3tm2.1Jxu involves: 129S4/SvJaeSor * 129S6/SvEvTac * C57BL/6	no abnormal phenotype detected	J:161101
Ncoa3tm2.2Jxu/Ncoa3tm2.2Jxu involves: 129S4/SvJaeSor * 129S6/SvEvTac * C57BL/6 * FVB/N	decreased body weight	J:161101
	decreased circulating insulin-like growth factor I level	J:161101